Lion's Mane and the Immune System
4 mechanisms through which lion's mane polysaccharides work in the gut: Peyer's patch activation, SIgA increase, tight junction repair, and microbiota reshaping
Sheng and colleagues (2017) established that lion's mane polysaccharides' immunomodulatory effects are mediated primarily through intestinal immunology: Peyer's patch activation and secretory immunoglobulin A (SIgA) induction. Tian (2023) added the specific tight junction proteins (ZO-1, occludin) that lion's mane repairs. Ren (2023) confirmed effects in cynomolgus monkeys.
Sheng et al., 2017; Tian et al., 2023
ZO-1 + occludin
the specific tight junction proteins restored by lion's mane polysaccharides in cyclophosphamide-immunocompromised mice (Tian et al., 2023), directly addressing the molecular mechanism of intestinal barrier repair
Monkey model
Ren and colleagues (2023) confirmed polysaccharide-driven colitis reduction and microbiota modulation in cynomolgus monkeys, the highest-organism preclinical evidence for lion's mane gut effects
Human pilot
Xie and colleagues (2021) documented gut microbiota changes from short-term lion's mane consumption in humans, providing the first direct human evidence for gut microbiome modulation
Sheng et al., 2017; Tian et al., 2023
View as image ↗Roughly 70 to 80% of the body's immune cells reside in tissue associated with the gut. The intestine is not just a digestive organ; it is the primary interface between the outside world (everything you eat and drink) and the immune system. Peyer's patches, which are clusters of immune tissue embedded in the intestinal wall, continuously sample intestinal contents and train the immune system to distinguish pathogens from food and beneficial bacteria.
Lion's mane polysaccharides work primarily through this gut-immune axis. Sheng and colleagues (2017) established the mechanism specifically: lion's mane polysaccharides' immunomodulatory effects are mediated through intestinal immunology, specifically through Peyer's patch activation and secretory immunoglobulin A (SIgA) induction. This is not a general anti-inflammatory effect happening in the bloodstream. It is a specific gut-based immune training mechanism. For context on what lion's mane is broadly, see what is lion's mane mushroom: a science-based overview.
Key Takeaways
- Sheng and colleagues (2017) established that lion's mane polysaccharides' immunomodulatory effects are mediated through intestinal immunology: Peyer's patch activation and increased secretory IgA (SIgA) production, the primary antibody protecting mucosal surfaces
- Tian and colleagues (2023) showed that lion's mane polysaccharides repair intestinal barrier proteins specifically: ZO-1 (zonula occludens-1) and occludin tight junction proteins were restored in cyclophosphamide-immunocompromised mice
- Ren and colleagues (2023) confirmed polysaccharide-driven colitis reduction and gut microbiota modulation in cynomolgus monkeys, the highest-organism preclinical evidence available for lion's mane gut effects
- Xie and colleagues (2021) documented gut microbiota composition changes in humans after short-term lion's mane consumption in a pilot study, providing the first direct human evidence for gut microbiome modulation
- Diling and colleagues (2017) showed lion's mane extracts relieve inflammatory bowel disease in mice by simultaneously regulating immunity and reshaping gut microbiota, connecting the immune and microbiome effects
- Lion's mane polysaccharides need to interact with the gut epithelium to exert their primary immune effects; taking them with food affects this interaction differently than taking them on an empty stomach
Four Mechanisms · One Gut-Immune Axis
How Lion’s Mane Polysaccharides Work in the Gut
Every documented effect runs through the intestine. The four pillars below are not separate stories — a healthier microbiome trains the immune tissue, immune tissue maintains the barrier, and the barrier keeps inflammation down. Each pillar is tagged with the highest organism in which it has been demonstrated.
Peyer’s patch activation
Molecular signature
SIgA ↑
Polysaccharides reach gut-wall immune tissue (Peyer’s patches) and raise secretory IgA — the antibody that coats mucosal surfaces. This is the route the article treats as primary: immune effects begin in the gut, not the bloodstream.
Tight-junction repair
Molecular signature
ZO-1 · occludin
In cyclophosphamide-immunocompromised mice, treatment restored the specific tight-junction proteins ZO-1 and occludin — the molecular definition of intestinal-barrier ("leaky gut") repair rather than a vague "gut health" claim.
Colitis / inflammation
Molecular signature
NF-κB ↓
Extracts relieved IBD by regulating immunity and microbiota (Diling); polysaccharide attenuated DSS colitis via NF-κB inhibition and lower oxidative stress (Ren). Confirmed in cynomolgus monkeys — the highest-organism preclinical evidence.
Microbiota reshaping
Molecular signature
dysbiosis → balance
Treatment shifted gut communities away from dysbiosis toward beneficial genera in immunocompromised mice, and short-term consumption changed microbiota composition in a human pilot — the one direct human data point.
“Highest organism” is the most human-like model in which each mechanism has been shown. Only microbiota change has any direct human data (an uncontrolled pilot); the barrier and Peyer’s-patch mechanisms remain mouse-level.
Source: Sheng et al. (2017); Diling et al. (2017); Ren et al. (2018); Tian et al. (2023, barrier); Tian et al. (2023, microbiota); Ren et al. (2023); Xie et al. (2021)
Peyer's Patches: Where Lion's Mane Meets the Immune System
Peyer's patches are organized clusters of immune tissue in the lining of the small intestine. They contain dendritic cells, macrophages, B cells, and T cells that continuously sample antigens from the gut lumen (the inside of the intestine). When Peyer's patches encounter a compound, they can either train the immune system to tolerate it or activate responses against it.
Sheng and colleagues (2017) tested what happens when lion's mane polysaccharides reach Peyer's patches.[1] The study directly titled its conclusion: the immunomodulatory effects of H. erinaceus polysaccharides are mediated by intestinal immunology. When the polysaccharides activated Peyer's patches, the result was increased production of secretory immunoglobulin A (SIgA).
SIgA is the antibody that coats mucosal surfaces throughout the body: the gut lining, the respiratory tract, and other surfaces exposed to the outside world. It is the first line of immune defense at these surfaces, neutralizing pathogens before they can penetrate the epithelium. Higher SIgA levels mean more effective mucosal immune defense.
The lion's mane polysaccharides' beta-glucan structure is recognized by Dectin-1 and Toll-like receptors on Peyer's patch immune cells, triggering activation. This is the same receptor recognition pathway through which beta-glucans from other fungi activate immune cells, but Sheng's study established that the primary route for lion's mane's systemic immune effects runs through the gut rather than direct bloodstream activation after absorption.
Sheng et al. (2017) · Food & Function
- Population
- Mice (intestinal immune tissue)
- Intervention
- Hericium erinaceus-derived polysaccharides
- Comparator
- Untreated controls
- Finding
- The immunomodulatory effects of the polysaccharides were mediated by intestinal immunology: Peyer's patch activation and increased secretory IgA, rather than direct systemic activation after absorption.
positive Establishes the gut-first mechanism the rest of this article builds on. Mouse-level evidence.
Sheng et al. (2017), Food & Function
Intestinal Barrier Repair: The ZO-1 and Occludin Evidence
The intestinal barrier is a single layer of epithelial cells connected by tight junction proteins. When these connections break down, the barrier becomes "leaky": bacterial products, food antigens, and inflammatory molecules pass into the bloodstream, triggering systemic inflammation. This is the biological basis of what is colloquially called "leaky gut."
The specific proteins that form tight junctions include ZO-1 (zonula occludens-1), occludin, and claudins. Measuring whether a compound repairs the intestinal barrier means measuring whether these specific proteins are restored.
Tian and colleagues (2023) tested lion's mane polysaccharides in mice with cyclophosphamide-induced immunocompromise, a model that damages intestinal barrier integrity alongside suppressing immune function.[4] The result: polysaccharide treatment ameliorated intestinal barrier injury, with specific improvements in ZO-1 and occludin protein expression in the intestinal epithelium.
This is the tight junction repair evidence that consumer content never discusses. The barrier repair is not a general "helps the gut" effect. It is specific restoration of the molecular components that physically maintain intestinal integrity. The fact that Tian identified the exact proteins involved makes this mechanistically credible rather than just observational.
IBD and Colitis: What Mouse Studies Show
Beyond barrier repair, lion's mane polysaccharides reduce active intestinal inflammation.
Diling and colleagues (2017) tested H. erinaceus extracts in a mouse model of inflammatory bowel disease and found that the extracts relieved IBD severity by simultaneously regulating immune function and reshaping gut microbiota composition.[2] The dual effect (immunity plus microbiome) is mechanistically consistent: gut immune dysregulation and microbiome dysbiosis co-occur in IBD; addressing both simultaneously produces better outcomes than targeting one alone.
Ren and colleagues (2018) investigated lion's mane polysaccharide specifically in a DSS-induced colitis model, finding attenuation of colitis through reduction of oxidative stress, inhibition of NF-kB signaling, and positive changes in gut microbiome composition.[3] NF-kB is the primary transcription factor driving intestinal inflammatory gene expression in IBD; its inhibition by lion's mane polysaccharides connects the gut-immune mechanism to the systemic anti-inflammatory effects documented in other lion's mane research.
The Monkey Model: The Highest-Organism Preclinical Evidence
Most lion's mane gut immunity research is in mice. Ren and colleagues (2023) went further, testing H. erinaceus mycelium-derived polysaccharide in cynomolgus monkeys with ulcerative colitis.[6]
Cynomolgus monkeys are much closer to humans than mice in terms of gut physiology, immune system organization, and microbiome composition. Evidence that works in monkeys is more likely to translate to humans than evidence from mouse models alone. This study is uncited in any consumer lion's mane content, despite being the most physiologically relevant preclinical evidence for the gut-immune effects.
The findings in the monkey model were consistent with what the mouse studies showed: polysaccharide treatment reduced ulcerative colitis severity and modulated gut microbiota composition toward a healthier profile. The microbiome changes included reduced abundance of pathogenic bacteria and increased abundance of beneficial bacterial genera.
Human Pilot Data: Short-Term Consumption Effects
Moving from animal models to humans, Xie and colleagues (2021) conducted a pilot study measuring the effects of short-term lion's mane consumption on serum biochemical markers and gut microbiota composition in human subjects.[7]
This is the only direct human evidence for lion's mane's gut microbiota effects. The study found that short-term consumption produced measurable changes in gut microbiota composition. Given that it was a pilot study without a placebo control arm, it provides directional evidence rather than confirmed clinical effect. But the microbiota changes documented were consistent with the mouse and monkey preclinical evidence, providing the first human data point in the gut-immune chain.
The Microbiota Dimension: Which Bacteria Change
A second 2023 study from Tian and colleagues specifically examined the gut microbiota changes from lion's mane polysaccharide treatment in cyclophosphamide-treated immunocompromised mice.[5] Cyclophosphamide (a chemotherapy drug) disrupts both immune function and gut microbiome composition, producing the kind of dysbiosis that increases infection risk and reduces immune defense.
Polysaccharide treatment shifted the microbiome in treated animals away from dysbiotic compositions and toward compositions with higher abundance of beneficial bacteria. The specific genera affected varied across studies, but the directional finding is consistent: lion's mane polysaccharides favor beneficial microbial communities over pathogenic ones.
This microbiota reshaping effect is mechanistically linked to the immune effects: gut microbiome composition directly influences Peyer's patch activation, SIgA production, and intestinal barrier integrity. A healthier microbiome means better-trained immune tissue in the gut wall. The polysaccharides produce both direct immune effects (Peyer's patch activation) and indirect immune effects (through microbiome improvement), working through interconnected pathways simultaneously.
Why Lion's Mane Should Be Taken With Food
The gut-first mechanism has a practical implication: lion's mane polysaccharides need to interact with gut epithelium, Peyer's patches, and the gut microbiome to exert their primary immune effects. This requires the polysaccharides to remain bioavailable in the gut lumen.
Taking lion's mane with food affects how quickly it moves through the gut and how concentrated it is at the intestinal surface when the immune cells are most accessible. The polysaccharides that drive the Peyer's patch activation, tight junction repair, and microbiome modulation are not absorbed in the same way as small molecules. They work at the gut surface and in the gut lumen, meaning their interaction time with gut tissue matters.
This is not a clinical recommendation about dosing timing; it is a mechanistic observation consistent with how gut-active polysaccharides from other sources work. For broader timing and dosing context, see can lion's mane help fight infections: antimicrobial evidence.
- Cell & receptor studiescompleted
Beta-glucan recognition by Dectin-1 and Toll-like receptors on gut immune cells is established.
- Animal modelscompleted
Mouse studies show Peyer's patch/SIgA activation, ZO-1 and occludin barrier repair, NF-kB-mediated colitis attenuation, and microbiota reshaping. Confirmed one step higher in cynomolgus monkeys (Ren 2023).
- Human pilotcurrent
One uncontrolled short-term pilot (Xie 2021) documented gut microbiota changes in humans. Directional only: no placebo arm.
- Randomized controlled trialmissing
No human RCT for gut, barrier, or IBD endpoints exists.
- Meta-analysismissing
Not yet possible without controlled human trials to pool.
The mechanism is well characterized in animals and reaches monkeys, but human evidence stops at a single uncontrolled pilot. Treat the gut-immune benefits as biologically plausible and preclinically strong, not clinically proven.
Sheng et al. (2017); Tian et al. (2023); Ren et al. (2018, 2023); Xie et al. (2021)
Context
ModeratePreclinical evidence is not a treatment claim
Concern
Almost all of the gut-immune evidence for lion's mane comes from mice, with one monkey study and one uncontrolled human pilot. None of it demonstrates that lion's mane treats leaky gut, IBD, ulcerative colitis, or any diagnosed condition in people.
What the research says
Read these findings as mechanism and plausibility, not as evidence that lion's mane should replace or supplement medical treatment for a gut condition.
Particularly relevant for: Anyone with diagnosed IBD, ulcerative colitis, Crohn's disease, or active gastrointestinal symptoms
What to do
Talk to your physician before using lion's mane for a gut or immune condition, especially if you take immunosuppressants or other prescribed therapy. This article is not medical advice.
Evidence base summarized above (Sheng 2017; Diling 2017; Ren 2018, 2023; Tian 2023; Xie 2021)
The Bottom Line
Lion's mane polysaccharides work primarily through intestinal immune mechanisms: Peyer's patch activation and SIgA induction (Sheng 2017), intestinal barrier repair via ZO-1 and occludin tight junction protein restoration (Tian 2023), IBD attenuation through NF-kB inhibition and microbiome modulation (Diling 2017, Ren 2018), and microbiota reshaping in immune-compromised mice (Tian 2023). Ren 2023 confirmed the effects in cynomolgus monkeys, the highest-organism preclinical evidence available. Xie 2021 documented gut microbiota changes in human subjects in a pilot study.
Frequently Asked Questions
Sources & References
- 1RTHM-00912·Sheng, Xiaotong et al. (2017). “Immunomodulatory effects of Hericium erinaceus derived polysaccharides are mediated by intestinal immunology..” Food & function.Study breakdown →PubMed →↩
- 2RTHM-00470·Diling, Chen et al. (2017). “Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota..” Oncotarget.Study breakdown →PubMed →↩
- 3RTHM-00529·Ren, Yilin et al. (2018). “Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota..” The Journal of nutritional biochemistry.Study breakdown →PubMed →↩
- 4RTHM-01803·Tian, Baoming et al. (2023). “Ameliorating effects of Hericium erinaceus polysaccharides on intestinal barrier injury in immunocompromised mice induced by cyclophosphamide..” Food & function.Study breakdown →PubMed →↩
- 5RTHM-01804·Tian, Baoming et al. (2023). “Modulating effects of Hericium erinaceus polysaccharides on the immune response by regulating gut microbiota in cyclophosphamide-treated mice..” Journal of the science of food and agriculture.Study breakdown →PubMed →↩
- 6RTHM-01776·Ren, Zhengyu et al. (2023). “Hericium erinaceus mycelium-Derived Polysaccharide Alleviates Ulcerative Colitis and Modulates Gut Microbiota in Cynomolgus Monkeys..” Molecular nutrition & food research.Study breakdown →PubMed →↩
- 7RTHM-01458·Xie, Xiao-Qian et al. (2021). “Influence of Short-Term Consumption of Hericium erinaceus on Serum Biochemical Markers and the Changes of the Gut Microbiota: A Pilot Study..” Nutrients.Study breakdown →PubMed →↩